Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy
AssigneesThe Board of Trustees of the Leland Stanford Junior University, The United States Government as represented by the Department of Veterans Affairs
InventorsJeffrey Louis Goldberg, Kun-Che Chang
Life of this patent
Estimating the term…
Abstract
An effective dose of Growth Differentiation Factor 15 (GDF15) is used for prevention or treatment of proliferative vitreoretinopathy. Specifically, the disclosure provides methods and compositions for treatment of proliferative vitreoretinopathy (PVR), which is based on preventing or reducing proliferation, cell migration, or epithelial-mesenchymal transition (EMT) of epithelial cells involved in PVR.
Claims16
A method for inhibiting or reducing the severity of proliferative vitreoretinopathy (PVR) in a human subject, the method comprising:
- contacting retinal pigment epithelial cells in an eye of the human subject with a composition comprising human growth differentiation factor 15 (GDF-15) in an amount sufficient to inhibit or reduce the severity of PVR.
Dependencies are inferred from the claim text.